SCHEMBL2275706

SCHEMBL2275706

O=C(Nc1cc(Oc2ccccc2)ccc1C(=O)O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.58
KCNK2 O95069 1/20 0.57
KCNK10 P57789 1/20 0.57
MAPK14 Q16539 2/20 0.56
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 1/20 0.55
HPSE Q9Y251 1/20 0.54
NR1H4 Q96RI1 1/20 0.52
IGF2BP2 Q9Y6M1 1/20 0.52
GALK1 P51570 1/20 0.52
CASP6 P55212 1/20 0.52
MCL1 Q07820 1/20 0.52
PLEC Q15149 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ACLY P53396 1/20 0.52
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
PYGL P06737 1/20 0.51
PYGM P11217 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272432 0.96 PYGL (0.55) SERPINE1KCNK2KCNK10MAPK14NPC1
SCHEMBL2269112 0.92 ACLY (0.59) SERPINE1KCNK2KCNK10HPSEACLY
SCHEMBL2277696 0.91 MPO (0.59) KCNK2KCNK10MAPK14HPSEPYGL
SCHEMBL2272613 0.90 LMNA (0.56) MAPK14NPC1RAB9AKMT2AACLY
SCHEMBL2292297 0.89 KCNK2 (0.62) SERPINE1KCNK2KCNK10MAPK14NPC1
SCHEMBL2271588 0.88 SERPINE1 (0.64) SERPINE1NPC1RAB9AKMT2AHPSE
SCHEMBL2273634 0.88 SERPINE1 (0.60) SERPINE1KCNK2KCNK10KMT2AHPSE
SCHEMBL2274737 0.87 AVPR2 (0.49) SERPINE1KCNK2KCNK10MAPK14KMT2A
SCHEMBL2293270 0.86 SERPINE1 (0.70) SERPINE1KCNK2KCNK10MAPK14NR1H4
SCHEMBL2276745 0.86 SERPINE1 (0.65) SERPINE1NPC1RAB9AKMT2AHPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SERPINE1 101/4885KCNK2 3527/4885KCNK10 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.